tiprankstipranks
Opthea Advances nAMD Treatment with Sozinibercept
Company Announcements

Opthea Advances nAMD Treatment with Sozinibercept

Opthea Limited Sponsored ADR (OPT) has released an update.

Don't Miss our Black Friday Offers:

Opthea Limited Sponsored ADR is making strides in the treatment of neovascular age-related macular degeneration (nAMD) by focusing on the VEGF-C and -D pathways. At the EURetina Symposium 2024, the company highlighted sozinibercept, a novel anti-VEGF-C & -D inhibitor, as an emerging therapy with the potential to set a new standard in visual outcomes. Despite the evolution of treatments targeting the VEGF pathway, there remains a significant portion of patients with suboptimal responses, indicating a strong need for innovative solutions like sozinibercept.

For further insights into OPT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskOpthea Limited Targets AMD Market with Sozinibercept
TheFlyOpthea appoints Kathy Connell to board of directors
TipRanks Auto-Generated NewsdeskOpthea Limited Strengthens Leadership and Advances AMD Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App